Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps by JAQUET, Antoine et al.
INFECTIOUS DISEASE EPIDEMIOLOGY (M YOTEBIENG, SECTION EDITOR)
Elimination of Viral Hepatitis in Low and Middle-Income Countries:
Epidemiological Research Gaps
Antoine Jaquet1 & Guy Muula2 & Didier K. Ekouevi1,3,4 & Gilles Wandeler5,6
Accepted: 30 March 2021
# The Author(s) 2021
Abstract
Purpose of Review The purpose of our review was to summarize current recommendations on testing strategies, antiviral therapy
eligibility and monitoring, and prevention of mother-to-child transmission of chronic hepatitis B virus (HBV) and hepatitis C
virus (HCV) infections, and to highlight major research gaps in low andmiddle-income countries (LMIC), with a particular focus
on sub-Saharan Africa (SSA).
Recent Findings While data on the prevalence of HBV and HCV infections in LMIC are increasing, current knowledge on liver-
related complications as well as on treatment outcomes remains limited. Furthermore, very little information is available on the
feasibility and cost-effectiveness of large-scale testing and management strategies in high-prevalence settings. The availability of
policy-relevant data is particularly scarce in SSA, which accounts for a significant part of the global burden of chronic viral
hepatitis.
Summary Current recommendations on the management and monitoring of chronic viral hepatitis rely mainly on data from high-
income settings. The global elimination of viral hepatitis will only be achieved if prevention, testing, and treatment strategies
tailored to specific LMIC are implemented. In order to inform scalable and cost-effective interventions, dedicated research
initiatives have to be undertaken. Future studies will have to include the evaluation of innovative testing strategies, the validation
of simplified methods to diagnose liver cirrhosis and hepatocellular carcinoma, and the monitoring of long-term treatment
outcomes and toxicity. In addition, national plans to achieve the elimination of HBV mother-to-child transmission are urgently
needed, including effective ways to test pregnant women, treat those who are eligible, and ensure birth dose vaccination is given
to all newborns.
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Introduction
Worldwide, chronic viral hepatitis infections cause over 1.3
million deaths per year, and account for half of liver cirrhosis
and hepatocellular carcinoma (HCC) cases [1–3••]. Although
chronic hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections affect 325 million people globally, fewer than 20%
of them are aware of their diagnosis, and less than 10% have
received appropriate antiviral therapy [3••]. These estimates
are generally lowest in the most affected regions: for instance,
the proportion of HBV infections diagnosed in 2015was 0.3%
in the African region and 2.3% in the Western Pacific region,
which account together for two thirds of HBV infections
globally.
In light of the increasing disease burden of chronic viral
hepatitis, the World Health Assembly endorsed the Global
Health Sector Strategy on viral hepatitis in 2016, and called
for the elimination of viral hepatitis as a public health threat by
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2030 [4]. The targets to be achieved by 2030 are ambitious: a
90% reduction in new cases and a 65% reduction in mortality
due to chronic HBV and HCV infections [3••]. Both targets
rely on the achievement of several specific objectives, includ-
ing massive improvements in delivery of interventions to re-
duce HBV mother-to-child transmission (MTCT), and uptake
of HBV and HCV testing and treatment. Reaching these ob-
jectives will depend on the successful implementation of
evidence-based interventions, adapted to specific regions
and populations. Still, many research gaps exist, especially
regarding the epidemiology, testing strategies, antiviral thera-
py eligibility, monitoring of treated individuals and prevention
of mother-to-child transmission of chronic viral hepatitis in
low- andmiddle-income countries (LMIC).We aimed to sum-
marize current recommendations on HBV and HCV testing
and management, including those from the World Health
Organization (WHO) and the European Association for the
Study of the Liver (EASL) [5••–9], and highlight the main
data gaps for LMIC (summarized in Table 1), with a focus
on sub-Saharan Africa (SSA). Addressing these important re-
search questions will be key in helping clinicians, policy
makers, and funders pave the way towards elimination of viral
hepatitis.
Current Evidence and Research Gaps
Across the Viral Hepatitis Care Cascade in Low
and Middle-Income Countries
Epidemiological Determinants and Testing Strategies
Detailed knowledge of the national and subnational HBV and
HCV epidemiological determinants is key for the implemen-
tation of sound testing strategies.
HBV Infection The prevalence and natural history of HBV
infection in LMIC have been relatively well characterized
over the last decades [10]. Based on the worldwide prevalence
of HBsAg carriage, countries are considered to have low
(<2%), intermediate (2–5%), or high (>5%) HBV prevalence.
However, these national HBV estimates are likely to change
over time as most LMIC have now implemented universal
HBV vaccination in children as part of their expanded immu-
nization program. Among the major indicators used by WHO
to monitor progress towards elimination of HBV is the num-
ber of new infections in children under 5 years old. Empirical
data on HBsAg carriage in this population is currently limited.
While modeling approaches can contribute to our understand-
ing of the burden of HBV infection and its dynamics, they will
not replace serological surveys in this age category. In this
specific population, a particular focus on infants exposed to
HBV infection will be of interest to assess the efficacy of
preventive interventions. In settings with an HBsAg preva-
lence ≥2% in the general population, focused testing in high
risk populations alone will be insufficient to identify most
individuals infected. Therefore, general population testing
for HBV infection is recommended in many LMIC. This strat-
egy implies the systematic testing of all adults regardless of
their age or risk, and raises many challenges. First, data on the
potential benefits of such an approach are very limited: A
recent mathematical modeling study based on data from
West Africa showed the cost-effectiveness of offering HBV
testing and treatment to the general population, even if the
prevalence was as low as 2% [11•]. Second, the implementa-
tion of such an approach raises many questions specific to
LMIC, considering the limited resources allocated to
healthcare and the absence of universal healthcare coverage.
Therefore, providing HBV testing to the general population
Table 1 Summary table of important research gaps
Epidemiological determinants and
testing strategies
1. How should HBV testing of the general population be implemented?
2. Is hepatitis delta infection a major threat in LMIC?
3. Is birth cohort testing for HCV infection the best way forward?
Antiviral therapy eligibility and
modalities
1. Should eligibility for antiviral therapy for HBV infection be more inclusive?
2. Do we know enough about long-term toxicity of TDF and TAF?
3. Can the evaluation of HBV-related cirrhosis be done using serological scores?
4. Should genotype be determined before anti-HCV therapy?
5. How can access to HCV therapy be improved?
Monitoring of treated individuals 1. Which HBV-infected individuals to screen for HCC in the absence of cirrhosis?
2. When can antiviral therapy for HBV infection be stopped?
3. Should SVR be monitored after antiviral therapy for HCV infection?
Prevention of mother-to-child
transmission
1. Which service delivery model is most effective for the provision of integrated HIV,
syphilis and hepatitis B testing and care for pregnant women?
2. Should TDF be prescribed regardless of HBV DNA level to prevent HBV MTCT if timely birth dose
vaccination is not available?
3. Should antiviral prophylaxis be continued after postpartum?
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will have to rely on a combination of strategies, including
provider-initiated and community-based testing.
HCV Infection The epidemiology of HCV infection differs
from HBV, with a more heterogeneous picture of HCV prev-
alence and transmission clusters, frequently linked to
healthcare interventions (exposure to infected blood through
unsafe injections) and risk behaviors (injection drug use)
[12, 13]. The local specificities of the epidemiological deter-
minants of HCV infection imply the need for more granular
data on HCV prevalence to prioritize populations and geo-
graphic areas in need of particular attention. This is particu-
larly true at a subnational level, where major regional varia-
tions are observed. For instance, in Burkina Faso, a national
survey based on the 2010–2011 Demographic and Health
Survey found a much higher HCV seroprevalence in the
South-West region (13.2%; 95% CI: 10.6–15.7) compared
to the national HCV seroprevalence (3.6%; 95% CI: 3.3–3.8)
[14]. Another major limitation in current knowledge about
HCV prevalence is the general lack of confirmation of active
chronic HCV infection in most studies. High rates of false-
positive HCV antibody tests have been reported in SSA,
especially in the context of HIV coinfection [15]. In order
to plan HCV management strategies and achieve appropriate
linkage to care, countries need to rely on estimates of con-
firmed, active HCV infections, which implies the availability
of affordable and accurate nucleic acid amplification tests.
Given their reduced cost, point-of-care HCV core antigen
tests may constitute a promising alternative to classical
HCV polymerase chain reaction [16]. The prevalence of
HCV infection being 2% in most LMIC, targeted strategies
focused on sub-groups of the population with a higher risk of
being infected are warranted.
Service Delivery of Testing for Viral Hepatitis in LMIC In set-
tings with weak healthcare systems, vertical health programs
supported by external funders such as HIV/AIDS or
Tuberculosis programs are particularly suited for systematic
viral hepatitis testing and should set the example for more
general testing. For instance, all persons living with HIV
(PLWH) should be tested for HBV, given the need for HIV/
HBV-coinfected individuals to receive tenofovir-containing
antiretroviral therapy (ART). Despite the progress made in
recent years, only a minority of PLWH are tested in clinical
routine, as shown in a recent multi-cohort study from SSA
[17]. According to WHO recommendations, HBV and HCV
screening of blood donors should be mandatory, and linkage
to care, counseling and treatment provided for those who test
positive. While testing is the rule in blood banks throughout
the world, notification and linkage to care of persons who test
positive is rarely implemented in LMIC. Another unique op-
portunity to implement facility-based testing would be the
antenatal clinic setting, albeit HBV testing, as opposed to
HIV, is not free of charge. Failing to test pregnant women
for HBV is a missed opportunity to prevent vertical transmis-
sion and to initiate antiviral therapy for womenwho need it for
their own health. Universal testing will ultimately require
broader provider-initiated testing approaches, including in
general healthcare facilities, where knowledge of viral hepati-
tis management is often minimal. Surveys performed in SSA
consistently highlighted the insufficient knowledge of viral
hepatitis prevention, testing and treatment among medical
practitioners as well as in the general population [18–21].
Eventually, only community-based testing strategies will al-
low reaching the majority of the general population, which
does not have access to provider-based testing. Studies eval-
uating the implementation of innovative outreach initiatives,
using rapid point-of-care tests and facilitated linkage to care,
are urgently needed.
Important Research Gaps
1. How should HBV testing of the general population be
implemented? Additional studies are needed to assess
the benefit of universal HBV testing to inform health pol-
icy in countries already confronted to many additional
health threats. Differentiated testing approaches prioritiz-
ing spouses, siblings, and household contacts of infected
persons, as well as healthcare workers, should be evalu-
ated. Such testing programs need to consider further di-
agnostic steps for HBsAg-positive individuals and evalu-
ation of treatment eligibility in decentralized settings.
2. Is hepatitis delta infection a major threat in LMIC?
Hepatitis delta causes the most severe form of viral hep-
atitis and increases the risk of liver-related mortality
among HBV-infected persons [22]. Although large
population-based studies have shown a prevalence of
HDV infection reaching >50% of HBsAg-positive per-
sons in some regions of Central Africa, estimates vary
widely across settings and even within countries [23,
24]. A more detailed knowledge of the burden of HDV
infection in LMIC is crucial to inform HBV care pro-
grams, as treatment options for HBV/HDV-coinfected in-
dividuals remain very limited.
3. Is birth cohort testing for HCV infection the best way
forward? In many regions of the world, including SSA,
a birth cohort effect on HCV prevalence has been shown;
for instance, the HCV seroprevalence was found to in-
crease dramatically with age in several areas of
Cameroon, reaching 50% of among individuals born be-
fore 1950 [25]. As the cost-effectiveness of testing strate-
gies focused on birth cohorts and high-risk groups has
been established, efforts should be made to identify high
prevalence populations across LMIC for intensified
screening.
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Antiviral Therapy Eligibility and Modalities
The overall goals of antiviral therapy for viral hepatitis are the
improvement of quality of life and the survival of infected
persons by decreasing the risk of liver cirrhosis and HCC.
Additional objectives are the prevention of transmission, for
example from the mother to the child, as well as the reduction
of symptoms related to extra-hepatic manifestations.
HBV Infection The immediate goals of antiviral therapy for
HBV infection are the suppression of HBV viral load and
the normalization of liver transaminases [5••, 8]. Among
HBeAg-positive individuals, conversion to HBeAg-
negativity occurs in 30–40% after 5 years of antiviral ther-
apy and leads to a phase of the infection with reduced ac-
tivity (HBeAg-negative chronic HBV infection). Finally,
HBsAg loss, also described as the functional cure of HBV
infection, is currently seen as the ideal outcome of antiviral
therapy, as it is associated with improvements in clinical
outcomes, reduction of HCC incidence, and allows the ces-
sation of antiviral therapy [26]. HBV functional cure gen-
erally occurs at a rate of 1% per person-year, but has been
shown to be more likely among HIV/HBV-coinfected indi-
viduals on tenofovir-containing ART [27•, 28]. Many cases
of active HBV infection will not require immediate antiviral
therapy but should instead undergo strict monitoring, which
consists of measurements of ALT, HBV DNA and liver
fibrosis at regular intervals, depending on the phase of the
infection. Table 2 summarizes current recommendations
regarding eligibility for antiviral therapy in chronic HBV
infection. In HIV/HBV co-infected individuals, tenofovir-
containing ART should be initiated in all patients, regard-
less of CD4 cell count. The mainstay of antiviral therapy for
HBV infection is the use of nucleoside analogues, including
tenofovir disoproxil fumarate (TDF), tenofovir alafenamide
(TAF), or entecavir, which lead to HBV suppression in
>90% of cases.
HCV Infection The immediate goal of antiviral therapy for
HCV infection is to achieve a sustained virologic response,
which is generally defined as the absence of HCV RNA in
serum 12 weeks after completion (SVR12) [6••, 7]. Antiviral
therapy for HCV infection should only be initiated in patients
with HCV RNA-confirmed infection. Treatment is recom-
mended for all patients with chronic HCV infection, except
those with a short life expectancy that cannot be remediated
by HCV therapy, liver transplantation, or another directed
therapy. The use of new generation direct-acting antivirals
(DAA) leads to SVR12 rates above 90% in treatment-naïve
individuals, independent of HCV genotype or fibrosis stage.
Two treatment regimens are favored as first-line therapy for
DAA-naïve individuals without cirrhosis or compensated cir-
rhosis: glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/
velpatasvir for 12 weeks [7]. Drug–drug interactions remain
a significant issue, especially in HIV-infected individuals
treated with DAA: for instance, the prescription of
sofosbuvir/velpatasvir or glecaprevir/pibrentasvir is contrain-
dicated if efavirenz is part of the ART regimen.
Important Research Gaps
1. Should eligibility for antiviral therapy for HBV infection
be more inclusive? Recent data have shown that potential
pre-carcinogenetic activity starts early in HBeAg-positive
individuals, despite the absence of overt liver damage
[29]. In addition, little is known on the incidence of
HCC among individuals infected during early childhood
in SSA, where they are exposed to other carcinogens,
such as aflatoxins. In the largest case series reported to
date, the age at HCC diagnosis was shown to be lower in
SSA than elsewhere [30•, 31]. Prospective studies inves-
tigating long-term liver-related complications of HBV in-
fection are urgent to inform treatment eligibility
guidelines.
Table 2 Eligibility criteria for antiviral therapy in chronic HBV infection
Treatment eligibility HBV viral load unavailable (WHO criteria) HBV viral load available (EASL criteria)
Must be treated - Presence of cirrhosis (clinical signs or based on
non-invasive measurement) regardless of ALT level
- Presence of chronic hepatitis B*
- Presence of cirrhosis and detectable HBV VL, regardless
of ALT level.
- Presence of HBV VL>2,000 IU/mL and ALT level
>2ULN, regardless of fibrosis
May be treated - Presence of chronic hepatitis B without cirrhosis but
persistently elevated ALT and age >30 years (in
particular)
- Presence of chronic HBeAg-positive HBV infection* and
age >30 years, regardless of fibrosis
- Presence of chronic HBV infection with family history of
HCC or cirrhosis, or with extrahepatic manifestations
*Chronic hepatitis B defined by HBV DNA >2,000 IU/ml, ALT >ULN, and/or at least moderate liver necro-inflammation or fibrosis. Chronic HBV
infection defined by persistently normal ALT and high HBV DNA levels
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2. Dowe know enough about long-term toxicity of TDF and
TAF? Although many studies have shown the association
between TDF and renal tubular toxicity among PLWH
[32], data from HBV-monoinfected individuals are
scarce. The use of TAF seems beneficial for HIV/HBV-
coinfected persons with renal dysfunction [33], but its
potential association with metabolic complications makes
it a questionable alternative [34]. More data are needed on
toxicity of nucleoside analogues in HBV-infected per-
sons, especially from regions where laboratory monitor-
ing is difficult to implement.
3. Can the evaluation of HBV-related cirrhosis be done
using serological scores? WHO recommends the use of
the APRI score to diagnose liver cirrhosis in settings
where transient elastography is not available [5••].
However, studies from large HBV cohorts in high-
income countries as well as in Ethiopia confirmed the
low diagnostic capacity of this score, which missed more
than 50% of cases of cirrhosis [35•, 36]. Efforts to develop
better non-invasive scores and to improve access to tran-
sient elastography or similar technologies are crucial.
4. Should genotype be determined before anti-HCV thera-
py? Recently, concerns have been raised on the efficacy
of current DAA regimens in the presence of specific sub-
genotypes mainly present in SSA. For example, SVR12
rates were 60% among patients with sub-genotype 4r
treated with sofosbuvir/ledipasvir in Rwanda [37•]. Data
on treatment outcomes with the newest generation DAA
combinations from SSA, including among individuals in-
fected with unusual sub-genotypes, are eagerly awaited.
5. How can access to HCV therapy be improved? Although
many LMIC are in the process of improving their access
to generic drugs, prices of DAA remain too high for many
countries, and many structural barriers impair the success-
ful expansion of HCV therapy. Lessons from the global
rollout of HIV therapy will be crucial to inform HCV
treatment strategies
Monitoring of Treated Individuals
In patients undergoing antiviral therapy, monitoring of
treatment toxicity and success is important. The number
and frequency of tests recommended have changed over
time, especially in the context of the use of safe and
potent DAA combinations for HCV. Table 3 shows the
monitoring procedures currently recommended for pa-
tients eligible for antiviral therapy.
Although there is some consensus on the frequency of lab-
oratory monitoring during and after antiviral therapy, many
questions are still open.
Important Research Gaps
1. Which HBV-infected individuals to screen for HCC in the
absence of cirrhosis? The poor prognosis of HCC when
diagnosed late justifies surveillance using 6-monthly ul-
trasound examinations in patients at high risk. Besides the
presence of liver cirrhosis, additional risk factors, includ-
ing age and sex, predict HCC in HBV-infected individ-
uals with or without HIV coinfection [38, 39•]. However,
previous studies have not focused on African populations,
where exposure to aflatoxin B1 may influence the risk of
HCC. Given the structural barriers to HCC screening in
LMIC, optimal risk stratification needs to be informed by
prospective cohort studies with long-term follow-up.
2. When can antiviral therapy for HBV infection be
stopped? In addition to patients with HBV functional
cure, those with sustained HBeAg loss have also been
considered for discontinuation of antiviral therapy [5••].
The potential for long-term toxicity of antiviral therapy
needs to be balanced against the risk of hepatitis flare after
its discontinuation. To date, no studies have evaluated the
pros and cons of this strategy in SSA. The potential im-
pact of treatment interruption strategies on clinical
Table 3 Monitoring of patients on antiviral therapy for HBV and HCV infections (adapted from WHO and European guidelines [5–8])
HBV HCV
Laboratory
Transaminases 3-monthly during year 1, 6-monthly thereafter At treatment start (3 months after the end of therapy)
Renal function 3-monthly during year 1, 6-monthly thereafter At treatment start and monthly during sofosbuvir treatment if renal
dysfunction at baseline
Viral load 3-monthly during year 1, 6–12-monthly thereafter Before treatment and 3 months after end of therapy (SVR12)





Every 2 years thereafter
Before treatment
No added value after SVR
Abdominal
ultrasound
6-monthly in individuals with cirrhosis and others at high
risk of HCC
6-monthly in individuals with cirrhosis or with F3 fibrosis + other
comorbidities
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outcomes and costs in LMIC, as well as the necessary
monitoring strategies after discontinuation, need to be
evaluated in dedicated studies.
3. Should SVR bemonitored after antiviral therapy for HCV
infection? According to EASL, checking SVR may be
dispensable in parts of the world with limited resources
for health, given the high SVR12 rates expected with
DAA-based regimens [7]. However, SVR monitoring
may remain indicated for groups of patients with a high
risk of reinfection or treatment failure. Future research
should help identify groups of patients for which close
monitoring is warranted in specific settings.
Prevention of Mother-to-Child Transmission
In LMIC, HBV is typically transmitted from the infected
mother to the child during birth or through household contact
during early childhood. Based on existing recommendations
on immunization from the WHO position paper in 2017, all
infants should receive their first dose of hepatitis B vaccine
within 24 h after birth, followed by two or three doses to
complete the primary series [3••]. Delivery of hepatitis B birth
dose vaccination should be a performance indicator for all
immunization programs, and reporting and monitoring sys-
tems should be strengthened to improve data quality.
However, only few LMIC have effectively introduced HBV
birth dose vaccination so far [40]: In SSA, where only 50% of
babies are delivered by a skilled birth attendant, coverage of
birth dose is estimated by WHO to be <10% [41]. According
to a meta-analysis including 31 studies from SSA published
before March 2017, the pooled coverage rates of HBV birth
dose was 1.3% (0.0–4.5) [42].
According to the recently published WHO guidelines
on HBV antiviral prophylaxis in pregnancy, women
testing positive for HBV infection with an HBV DNA
≥ 5.3 log10 IU/mL (≥ 200,000 IU/mL) should receive
TDF prophylaxis from the 28th week of pregnancy to
prevent MTCT [43••]. In settings in which antenatal
HBV DNA testing is not available, HBeAg testing can
be used as an alternative to HBV DNA to determine
eligibility for antiviral prophylaxis. However, estimates
of the effectiveness of testing and antiviral prophylaxis
of pregnant women, in addition to HBV birth dose vac-
cination, essentially rely on data from Asia, where the
determinants of HBV transmission are different from
SSA.
Important Research Gaps
1. Which service delivery model is most effective for the pro-
vision of integrated HIV, syphilis, and viral hepatitis testing
and care for pregnant women? Improving testing and treat-
ment of these conditions in prenatal care is urgent, but not
enough. A significant proportion of births occur outside of
healthcare services and many women do not have access to
antenatal care. Thus, innovativemodels of decentralized test-
ing and birth dose vaccination considering local specificities
and structural barriers will have to be evaluated.
2. Should TDF be prescribed regardless of HBVDNA level to
prevent HBV MTCT if timely birth dose vaccination is not
available? In some settings, antiviral prophylaxis is pre-
scribed to prevent MTCT based on a single positive
HBsAg test, in the absence of HBV viral load assessments.
The efficacy and safety of this pragmatic approach should be
evaluated. Conversely, if treatment eligibility has to be based
on the level of HBV replication, POC HBeAg tests and/or
DBS-based viral load testing need to be urgently validated.
3. Should antiviral prophylaxis be continued after postpartum?
The incidence of hepatitis flares after the interruption of TDF
prophylaxis is largely unknown, and women in LMIC are
likely to experience subsequent pregnancies with the need to
start antiviral prophylaxis during these pregnancies. In anal-
ogy to pragmatic decisions taken to address HIV MTCT in
SSA [44], the feasibility and efficacy of continuous antiviral
prophylaxis for women in childbearing age need to be
assessed in large-scale studies.
Conclusions
Despite recent advances in HBV and HCV management
over the past decade, our review highlights the many
challenges on the road to viral hepatitis elimination as
a public health threat by 2030 in LMIC. Reducing viral
hepatitis mortality by 65% globally will not be possible
unless major improvements occur throughout the cas-
cade of care. Importantly, countries should focus on
achieving viral hepatitis elimination targets with their
own service coverage initiatives that will have the max-
imum impact [45]. Provider-initiated and community-
based strategies will have to be implemented in most
LMIC to reach general population HBV testing, whereas
HCV testing strategies will have to focus on most af-
fected populations and consider birth cohorts. Dedicated
research initiatives will have to evaluate affordable and
scalable diagnostic procedures to detect liver fibrosis
and screen for HCC in decentral ized set t ings.
Widespread access to antiviral therapy for eligible
HBV-infected and HCV-infected individuals has to be
guaranteed, and the capacity for the systematic monitor-
ing of its efficacy and safety improved. Finally, there
will be no elimination of HBV in LMIC without the
prevention of MTCT: HBV testing of all pregnant
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women, as well as antiviral prophylaxis for those with
high viral loads, and HBV birth dose vaccination for all
newborns should be priorities for all countries [46].
To help address the challenges ahead, it will be cru-
cial to learn the lessons from the fight against HIV in
settings where the implementation of testing and treat-
ment is challenging [47]. The tools to prevent, diagnose,
and treat viral hepatitis are known and available.
However, reaching the ambitious objectives set for elim-
ination will depend on the strong commitment from the
international community as well as from governments of
the most affected countries to support the scale-up of
key interventions. Current guidelines on viral hepatitis
treatment and monitoring have been mostly based on
data from high-income countries, where healthcare sys-
tems and the natural history of chronic viral hepatitis
infections are different from SSA. Well-designed imple-
mentation science and clinical research studies from
LMIC will be key in closing epidemiological data gaps
and informing innovative and cost-effective strategies to
be implemented at a large scale.
Author Contribution Antoine Jaquet (AJ), Guy Muula (GM), Didier
Ekouevi (DE), and Gilles Wandeler (GW) planned the review, wrote
the first draft of the manuscript, and agreed on its final version.
Funding Open Access funding provided by Universität Bern. This study
was supported by the National Institute of Allergy and Infectious
Diseases (Grants number 5U01AI069924-05 and U01AI069919). GW
was supported by a Professorship (PP00P3_176944) from the Swiss
National Science Foundation.
Declarations
Conflict of Interest Gilles Wandeler reports grants from Gilead Sciences,
grants from ViiV, outside the submitted work. Antoine Jaquet, Guy Muula,
and Didier Ekouevi declare that they have no conflict of interest
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of the
authors.
Disclaimer The content is solely the responsibility of the authors and
does not represent the official views of the funders.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Collaborators GBDC. The global, regional, and national burden of
cirrhosis by cause in 195 countries and territories, 1990-2017: a
systematic analysis for the Global Burden of Disease Study 2017.
Lancet Gastroenterol Hepatol. 2020;5(3):245–66.
2. Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S,
Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary
liver cancer and underlying etiologies from 1990 to 2015 at the global,
regional, and national level: results from the Global Burden of Disease
Study 2015. JAMA Oncol. 2017;3(12):1683–91.
3.•• Global Hepatitis Report 2017. Geneva: World Health Organization;
2017. available at http://apps.who.int/iris/bitstream/handle/10665/
255016/9789241565455-eng.pdf?sequence=1 Last accessed [10/10/
2020].
4. World Health Organization. Global Health Sector Strategy on Viral
Hepatitis 2016–2021: towards ending viral hepatitis WHO/HIV/
2016.06. Available at: http:// www.who.int/hepatitis/strategy2016-
2021/ghss-hep/en/. Accessed September 15, 2020.
5.•• Guidelines for the prevention, care and treatment of persons with
chronic hepatitis B infection. Geneva, World Health Organisation
2015. available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-
b-guidelines/en/ [Last accessed 8/17/2018].
6.•• World Health Organization (WHO). Guidelines for the care and
treatment of persons diagnosed with chronic hepatitis C virus in-
fection. Geneva, 2018 available at https://www.who.int/hepatitis/
publications/hepatitis-c-guidelines-2018/en/ accessed 10/05/2020.
7. European Association for the Study of the Liver. Electronic address
eee, Clinical Practice Guidelines Panel C, representative EGB,
Panel m. EASL recommendations on treatment of hepatitis C:
Final update of the series(). J Hepatol. 2020.
8. European Association for the Study of the Liver. Electronic address
eee, European Association for the Study of the L. EASL 2017
Clinical Practice Guidelines on the management of hepatitis B virus
infection. J Hepatol. 2017;67(2):370–98.
9. WHO. Guidelines on Hepatitis B and C Testing. Geneva: WHO
Guidelines Approved by the Guidelines Review Committee; 2017.
10. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ.
Estimations of worldwide prevalence of chronic hepatitis B virus
infection: a systematic review of data published between 1965 and
2013. Lancet. 2015;386(10003):1546–55.
11.• Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S,
et al. Cost-effectiveness of community-based screening and treat-
ment for chronic hepatitis B in The Gambia: an economic model-
ling analysis. Lancet Glob Health. 2016;4(8):e568–78.
12. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global
epidemiology of hepatitis C virus infection: new estimates of age-
specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):
1333–42.
13. Grebely J, Larney S, Peacock A, Colledge S, Leung J, HickmanM,
et al. Global, regional, and country-level estimates of hepatitis C
95Curr Epidemiol Rep (2021) 8:89–96
infection among people who have recently injected drugs.
Addiction. 2019;114(1):150–66.
14. Meda N, Tuaillon E, Kania D, Tiendrebeogo A, Pisoni A, Zida S,
et al. Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-
sectional study. Bull World Health Organ. 2018;96(11):750–9.
15. Mullis CE, Laeyendecker O, Reynolds SJ, Ocama P, Quinn J, Boaz
I, et al. High frequency of false-positive hepatitis C virus enzyme-
linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis.
2013;57(12):1747–50.
16. Mohamed Z, Mbwambo J, Shimakawa Y, Poiteau L, Chevaliez S,
Pawlotsky JM, et al. Clinical utility of HCV core antigen detection and
quantification using serum samples and dried blood spots in people who
inject drugs in Dar-es-Salaam, Tanzania. J Int AIDS Soc. 2017;20(1):
21856.
17. Coffie PA, Egger M, Vinikoor MJ, Zannou M, Diero L, Patassi A,
et al. Trends in hepatitis B virus testing practices and management
in HIV clinics across sub-Saharan Africa. BMC Infect Dis.
2017;17(Suppl 1):706.
18. Debes JD, Kayandabila J, Pogemiller H. Knowledge of hepatitis B
transmission risks among health workers in Tanzania. Am J Trop
Med Hyg. 2016;94(5):1100–2.
19. Djaogol T, Coste M, Marcellin F, Jaquet A, Chabrol F, Giles-
Vernick T, et al. Prevention and care of hepatitis B in the rural region
of Fatick in Senegal: a healthcare workers' perspective using a mixed
methods approach. BMC Health Serv Res. 2019;19(1):627.
20. Jaquet A,Wandeler G, Tine J, DialloMB,MangaNM, Dia NM, et al.
Prevention and care of hepatitis b in Senegal; awareness and attitudes
of medical practitioners. Am J Trop Med Hyg. 2017;97(2):389–95.
21. Mudji J, Madinga B, Horsmans Y. Seroprevalence of viral hepatitis
B and C and knowledge of the hepatitis B virus among pregnant
women attending prenatal care in the Democratic Republic of
Congo. Am J Trop Med Hyg. 2021;104(3):1096–100.
22. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de
Franchis R, et al. A 28-year study of the course of hepatitis Delta
infection: a risk factor for cirrhosis and hepatocellular carcinoma.
Gastroenterology. 2009;136(5):1629–38.
23. Besombes C, Njouom R, Paireau J, Lachenal G, Texier G,
Tejiokem M, et al. The epidemiology of hepatitis delta virus infec-
tion in Cameroon. Gut. 2020;69(7):1294–300.
24. Stockdale AJ, Chaponda M, Beloukas A, Phillips RO, Matthews
PC, Papadimitropoulos A, et al. Prevalence of hepatitis D virus
infection in sub-Saharan Africa: a systematic review andmeta-anal-
ysis. Lancet Glob Health. 2017;5(10):e992–e1003.
25. Nerrienet E, Pouillot R, Lachenal G, NjouomR,Mfoupouendoun J,
Bilong C, et al. Hepatitis C virus infection in cameroon: a cohort-
effect. J Med Virol. 2005;76(2):208–14.
26. Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, et al.
HBsAg seroclearance further reduces hepatocellular carcinoma risk
after complete viral suppression with nucleos(t)ide analogues. J
Hepatol. 2019;70(3):361–70.
27.• Chihota BV, Wandeler G, Chilengi R, Mulenga L, Chung RT,
Bhattacharya D, et al. High rates of hepatitis B virus (HBV) func-
tional cure among human immunodeficiency virus-HBV
coinfected patients on antiretroviral therapy in Zambia. J Infect
Dis. 2020;221(2):218–22.
28. Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and effi-
cacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int.
2018;38(Suppl 1):84–9.
29. Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, et al. HBV
DNA Integration and clonal hepatocyte expansion in chronic hep-
atitis B patients considered immune tolerant. Gastroenterology.
2016;151(5):986–98 e4.
30.• Yang JD, Mohamed EA, Aziz AO, Shousha HI, Hashem MB,
Nabeel MM, et al. Characteristics, management, and outcomes of
patients with hepatocellular carcinoma in Africa: a multicountry
observational study from the Africa Liver Cancer Consortium.
Lancet Gastroenterol Hepatol. 2017;2(2):103–11.
31. Yang JD, Gyedu A, Afihene MY, Duduyemi BM, Micah E,
Kingham TP, et al. Hepatocellular carcinoma occurs at an earlier
age in Africans, particularly in association with chronic hepatitis B.
Am J Gastroenterol. 2015;110(11):1629–31.
32. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M.
Systematic review andmeta-analysis: renal safety of tenofovir disoproxil
fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505.
33. Surial B, Beguelin C, Chave JP, Stockle M, Boillat-Blanco N,
Doco-Lecompte T, et al. Switching from TDF to TAF in HIV/
HBV co-infected individuals with renal dysfunction-a prospective
cohort study. J Acquir Immune Defic Syndr. 2020;85(2):227–32.
34. Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser
S, et al. Weight gain following initiation of antiretroviral therapy:
risk factors in randomized comparative clinical trials. Clin Infect
Dis. 2020;71(6):1379–89.
35.• Aberra H, DesalegnH, BerheN,MekashaB,Medhin G, Gundersen
SG, et al. The WHO guidelines for chronic hepatitis B fail to detect
half of the patients in need of treatment in Ethiopia. J Hepatol.
2019;70(6):1065–71.
36. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al.
Evaluation of APRI and FIB-4 scoring systems for non-invasive
assessment of hepatic fibrosis in chronic hepatitis B patients. J
Hepatol. 2016;64(4):773–80.
37.• Gupta N, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi
CM, Shumbusho F, et al. Treatment of chronic hepatitis C virus
infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a
single-arm trial. Lancet Gastroenterol Hepatol. 2019;4(2):119–26.
38. Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van
Boemmel F, Buti M, et al. Hepatocellular carcinoma prediction
beyond year 5 of oral therapy in a large cohort of Caucasian patients
with chronic hepatitis B. J Hepatol. 2020;72(6):1088–96.
39.• Wandeler G, Mauron E, Atkinson A, Dufour JF, Kraus D, Reiss P,
et al. Incidence of hepatocellular carcinoma in HIV/HBV-
coinfected patients on tenofovir therapy: relevance for screening
strategies. J Hepatol. 2019;71(2):274–80.
40. Moturi E, Tevi-Benissan C, Hagan JE, Shendale S, Mayenga D,
Murokora D, et al. Implementing a birth dose of hepatitis B vaccine
in Africa: findings from assessments in 5 countries. J Immunol Sci.
2018;Suppl(5):31–40.
41. WHO/UNICEF estimates of national immunization coverage
avialble at https://www.who.int/immunization/monitoring_
surveillance/data/en/ accessed September 15 2020.
42. Bassoum O, Kimura M, Tal Dia A, Lemoine M, Shimakawa Y.
Coverage and timeliness of birth dose vaccination in Sub-Saharan
Africa: a systematic review and meta-analysis. Vaccines (Basel).
2020;8(2):301.
43.•• WHO. Prevention of mother-to-child transmission of hepatitis B
virus: guidelines on antiviral prophylaxis in pregnancy. Geneva:
WHO Guidelines Approved by the Guidelines Review
Committee; 2020.
44. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A,
Chirwa Z, et al. Prevention of mother-to-child transmission of HIV
and the health-related Millennium Development Goals: time for a
public health approach. Lancet. 2011;378(9787):282–4.
45. Polaris Observatory C. The case for simplifying and using absolute tar-
gets for viral hepatitis elimination goals. J Viral Hepat. 2021;28(1):12–9.
46. Wilson P, Parr JB, Jhaveri R, Meshnick SR. Call to action: preven-
tion of mother-to-child transmission of hepatitis B inAfrica. J Infect
Dis. 2018;217(8):1180–3.
47. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T,
Kamarulzaman A, et al. Expanding access to treatment for hepatitis
C in resource-limited settings: lessons from HIV/AIDS. Clin Infect
Dis. 2012;54(10):1465–72.
96 Curr Epidemiol Rep (2021) 8:89–96
